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Osteoporosis is a growing problem worldwide. In
1997 a World Health Organization report1 estimated
that approximately 380 million people 65 years or
older were affected by osteoporosis, and this figure
is expected to rise to 690 million by 2020. Considering
that osteoporosis affects mostly elderly people (includ-
ing approximately 1 in 3 postmenopausal women),2 it
is not surprising that the World Health Organization
Bone and Joint Decade predicts that the number of
hip fractures associated with osteoporotic changes
will increase from 1.7 million in 1990 to 6.3 million by
2050 unless preventive programs are introduced.3 In
the United Kingdom, as elsewhere, the morbidity as-
sociated with osteoporosis not only diminishes quali-
ty of life4, 5 but also incurs significant financial costs
to health-care providers. For example, in 1998 Dolan
and Torgerson6 reported that osteoporotic fractures
cost the National Health Service approximately £942
million annually. More recently, the National Service
Framework for Older People7 indicated that 14,000
people died as a direct result of an osteoporotic hip
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fracture and that 50% of those who survived cannot
live independently. These statistics support the view
proposed by the 1997 World Health Organization re-
port1 that “pain, suffering, loss of physical capacity
and social impairment” were the prices paid by those
living longer and consequently at increased risk for
chronic musculoskeletal complaints, including osteo-
porosis and rheumatoid arthritis.
Osteoporosis is not only a disease of the frail elder-
ly. It has a multifactorial etiology, reviewed in detail
elsewhere.8-10 A significant proportion of patients with
rheumatoid arthritis are subsequently diagnosed as
having osteoporosis, the etiologic factors of which
are reviewed in Table 1.11-15 The pathogenesis of rheu-
matoid arthritis–associated osteoporosis is a com-
plex, multifactorial process that includes the effect of
proinflammatory cytokines, medication, and post-
menopausal hormone loss, making risk assessment
difficult.16 People with rheumatoid arthritis have a
greater risk of fracture associated with reduced bone
mineral density, particularly in connection with corti-
costeroid treatment.17-20 However, the precise hierar-
chy of risk factors for osteoporotic fractures requires
further epidemiologic research.21, 22
The prevention and management of osteoporosis
is a key aim of the National Service Framework for
Older People7 because it can have a significant effect
on the number and cost of fractures. Beardsworth
and Purdie23 consider that the immediate future lies
in selectively screening individuals with recognized
risk factors. In primary care, preventing the first frac-
ture by identifying and treating those at risk for os-
teoporosis is also a key aim.24 A variety of treatment
strategies are reported in the literature, including di-
etary modification, calcium and vitamin D supple-
mentation, weightbearing exercise, hormone therapy,
and bisphosphonate use.16, 25 In terms of identifica-
tion, osteoporosis is defined on the basis of bone den-
sity. The quantitative definition of osteoporosis is a
bone mineral density value less than 2.5 SD below the
adult mean value.26 The current gold standard for
quantifying bone mineral density is dual-energy x-ray
absorptiometry (DEXA), which provides high resolu-
tion and is quick, precise, and accurate.11 However,
DEXA is rarely used in the primary-care setting,
where most regular patient contacts occur for individ-
uals at high risk for osteoporosis, partly because of
the need for bulky and expensive equipment. More re-
cently, newer screening tools have become available,
in particular noninvasive quantitative ultrasound ma-
chines, which are cheaper, smaller, and more porta-
ble, making them ideal for use in primary-care set-
tings. Njeh et al27 suggest that because quantitative
ultrasound is an accepted tool for the measurement
of bone mineral density, it could be used to screen for
bone changes in patients with rheumatoid arthritis.
However, others argue that further research needs to
be undertaken regarding the diagnostic precision of
quantitative ultrasound before it is used as a screen-
ing tool in widespread clinical practice.11 The aim of
this study was to determine whether contact ultra-
sound bone analysis (CUBA) calcaneal scanning is a
reliable measure for osteoporosis in people with rheu-
matoid arthritis.
Methods
Patients and Setting
Fifty patients with a diagnosis of rheumatoid arthritis
(according to the 1987 American Rheumatism Associ-
ation criteria28) were recruited from a rheumatology
outpatient department; sampling was purposeful and
convenience based. Patients with concomitant sys-
temic disease, including previous cerebrovascular ac-
cident, diabetes mellitus, and inflammatory arthropa-
thies other than rheumatoid arthritis, were excluded,
as were amputees, those with previous fractures of
the wrist or calcaneus, and pregnant women. Patients
underwent a DEXA scan of the nondominant wrist
and a CUBA scan of the heel (on the same side as the
wrist scan). Data were collected in the hospital outpa-
tient department for 2 months, coinciding (where pos-
sible) with patients’ normal appointments.
All of the participants gave written informed con-
sent, and ethical approval was granted by Brighton &
Hove Primary Care Group research ethics committee
for this study. Bone density measurements were per-
formed as part of ongoing local research into the role
of primary-care providers undertaking routine screen-
ing of “at-risk” populations to facilitate more appro-
priate referral and care pathways. This study used a
comparative trial design focusing on within-group
comparisons.
Table 1. Etiologic Factors Associated with Osteoporosis
in Rheumatoid Arthritis
Immobility and habitual underuse of full range of motion
Periarticular osteoporosis reflecting disease activity
Loss of systemic bone remodeling
Secondary to long-term corticosteroid use
Nutritional deficiency
Methotrexate use
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Clinical Data
Participants provided demographic details and com-
pleted an osteoporosis status questionnaire of up to
21 items, including open and closed questions that
considered the symptoms of osteoporosis, family his-
tory, current treatment for osteoporosis, and previous
bone density measurements.
Bone Density Measurements
Bone mineral density and bone mineral content were
measured at the distal forearm using a peripheral
densitometer (model DTX-200; Churchill Medical Ltd,
Northants, England). The forearm is placed in a shaped
container where a high-voltage (55-kV) pencil-beam x-
ray source is located on one side of the forearm and a
detector on the other side. In rheumatoid arthritis, the
hand and forearm is a principal site of inflammation
and synovitis. Bone mineral density measurements of
this site are considered important because levels of
periarticular osteoporosis have been shown to reflect
disease activity.29, 30 The participant’s nondominant
side was measured because differences in bone den-
sity between dominant and nondominant hands may
yield higher values on the dominant side.31, 32
Quantitative ultrasound was used to measure bone
ultrasonic attenuation at the calcaneus using the CUBA
clinical instrument (McCue Ultrasonic, Winchester,
England). Two transducers (receiving and emitting)
faced with silicone rubber coupling pads were placed
in direct contact on either side of the calcaneus using
a coupling gel (Fig. 1). Participants underwent single
scan measurements of the calcaneus on the same side
as the DEXA wrist scan. Characterization parameters
measure the velocity of sound and broadband ultra-
sonic attenuation. Owing to its larger surface area,
trabecular bone is metabolically more active and so
more readily affected by factors that may cause bone
loss.33 Therefore, bone loss is most rapid in areas of
the skeleton with the highest proportion of trabecular
bone.34 In common with other sites usually assessed
for osteoporotic changes, such as the vertebrae, the
calcaneum is 95% trabecular bone, making it a suit-
able site for determining osteoporotic changes.
Repeatability and Reliability
Before patient assessment using the DEXA unit, a qual-
ity-control phantom scan was performed on a phan-
tom with a known bone mineral content of 3.618 g to
ensure correct calibration. In accordance with manu-
facturer guidelines, a standard phantom was used to
calibrate the CUBA unit before the study. Intratester
and intertester reliability tests did not demonstrate sig-
nificance at the 5% level, suggesting that the primary
researcher (J.R.C.) was producing consistent meas-
urements on the same patients using the same ma-
chine.
Statistics
The results of the DEXA unit and the bone ultrasonic
attenuation t score of the CUBA unit were compared
using the Spearman rank correlation coefficient to
determine the relationship between the values of
these two variables. To assess the usefulness of the
CUBA unit in clinical practice, the sensitivity, speci-
ficity, and positive and negative predictive values
were also calculated. Sensitivity refers to the propor-
tion of participants with osteoporosis as determined
by a DEXA scan and then correctly identified by the
CUBA scan, whereas specificity is the proportion of
participants without osteoporosis correctly identified
by the CUBA scan. These data are presented as per-
centages. The positive predictive value refers to the
proportion of participants with positive CUBA scan
findings who have osteoporosis. The negative predic-
tive value is the proportion of participants with nega-
tive CUBA scan findings who do not have osteoporo-
sis; both data sets are expressed as percentages.
Results
Forty-six participants completed the trial and four
withdrew (one moved away, one had an emergency
surgical admission, and two did not complete data
collection). The demographic and clinical character-
Figure 1. Contact ultrasound bone analysis (CUBA)
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istics of the participants are listed in Table 2. The cor-
relations obtained for the DEXA and CUBA scanners
suggest a weak positive association between the two
variables (ρ = 0.341; P = .02) (Fig. 2). The DEXA wrist
scans identified 78% of the participants as having nor-
mal bone density and the remaining 22% as having os-
teoporosis. In contrast, the CUBA heel scans identi-
fied 37% of the patients as having normal bone density
and the remaining 63% as having osteoporosis (Table
3). Currently, DEXA is the accepted method of diag-
nosing osteoporosis; therefore, these data suggest that
of the CUBA scanner findings, 20% are true-positive
osteoporosis results and 35% are true-negative results,
with 43% being false-positive osteoporosis results and
2% being false-negative results. Using the clinical data
from Table 2, sensitivity of the CUBA unit was high
(90%) but specificity was lower (44%); the positive
predictive value of the CUBA unit was 31% and the
negative predictive value was 94%.
Discussion
The results of this study suggest that the CUBA unit
may have limited usefulness in diagnosing osteoporo-
sis from a calcaneal scan in a population with rheu-
matoid arthritis. Specificity for diagnosing bone min-
eral density–defined osteoporosis was low (31%), but
sensitivity remained high (94%). Therefore, these re-
sults indicate that if a normal bone density value is
obtained using the CUBA unit, there is 94% certainty
this is correct. However, if osteoporosis is diagnosed,
there is only 31% certainty this is correct, given a re-
ported precision error of ±1% for the DEXA unit.35 The
results of this study indicate that there could be a use-
ful role for the CUBA unit not as a screening tool for
osteoporosis but as a screening tool for normal bone
density. Primary-care clinicians may increasingly in-
corporate ultrasound densitometry into their practice
because of its low cost and portability, giving a wider
applicability (eg, use in people’s homes), something
DEXA units cannot currently offer.36, 37 In addition,
some patients with advanced disease may have se-
vere ulnar deviation, making it impossible to use port-
able DEXA wrist scanners, or may be unsuitable for
DEXA scanning owing to the presence of a prosthetic
joint used in total hip replacement. In such cases,
using the CUBA unit to screen for normal bone densi-
ty may be more appropriate.
The correlation between the CUBA and DEXA
units was weakly positive (ρ = 0.341). This correlation
is broadly similar to that of other studies in which dif-
ferent anatomical sites were assessed. Imamoto et al38
Table 2. Demographic and Clinical Characteristics of the
46 Study Participants
Characteristic Value
Sex (No. [%])
M 11 (24)
F 35 (76)
Age (mean [range]) (years) 61 (26–91)
Height (mean [range]) (cm) 166.9 (147.3–188)
Body weight (mean [range]) (kg) 72.3 (43.5–111)
Current or previous smokers (%) 35
Previous fracture (other than wrist  21
or calcaneum) (%)
Previous corticosteroid use (%)a 42
Previous bisphosphonate therapy (%)a 54
Right-handed (%)b 83
aNo participants were currently taking corticosteroids or
bisphosphonates.
bAll of the scans were undertaken on the nondominant
side.
Figure 2. T scores obtained using the dual-energy x-
ray absorptiometry (DEXA) and contact ultrasound
bone analysis (CUBA) scanners. BUA indicates bone
ultrasonic attenuation.
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Table 3. Relationship Between Results of the DEXA Wrist
Scan and the CUBAHeel Scan in the 46 Study Participants
DEXA
Osteoporosis Normal Total
CUBA
Test positive 9 20 29
Test negative 1 16 17
Total 10 36 46
Abbreviations: DEXA, dual-energy x-ray absorptiometry;
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reported in cadaveric studies a correlation between
bone mineral density and bone ultrasonic attenuation
of r = 0.39. Tromp et al39 compared quantitative ultra-
sound measurements of the calcaneum with DEXA
measurements of the lumbar spine, femoral neck,
greater trochanter, and total body, yielding r values of
0.41, 0.35, 0.45, and 0.47, respectively. Regarding sen-
sitivity and specificity, Naganathan et al40 reported a
sensitivity of CUBA calcaneal scanning of 9% to 47%
and a specificity of 88% to 100%. However, these stud-
ies compared quantitative ultrasound of the calcaneum
with axial DEXA measurements. It is recommended
that appendicular and axial skeletal sites are meas-
ured (most commonly the lumbar spine and hip10);
this approach is expensive, requires bulky equipment,
and necessitates using ionizing radiation.41
In this study, a higher proportion of participants
were identified as having osteoporosis using the CUBA
scanner (63%) compared with DEXA (22%). Radio-
graphic studies42-45 have repeatedly shown that in
rheumatoid arthritis, periarticular erosions seem to
occur earlier and possibly more frequently in the feet
than in the hands. Considering the interaction be-
tween inflammatory synovitis and mechanical stress,46
it is possible that participants in this study have more
osteoporotic damage in their feet. This has led to fur-
ther speculation45 that periarticular erosions in the
foot may be more common owing to the subluxation
of joints commonly observed in the feet of individuals
with rheumatoid arthritis. 
Involvement of the rearfoot in rheumatoid arthritis
has been reported to affect 42% to 80% of patients
with rheumatoid arthritis,47-49 often leading to a valgus
deformity of the rearfoot. Although not measured in
this study, valgus calcaneal drift may have implica-
tions for quantitative ultrasound studies of the calca-
neum. Gluer et al50 found that the bone ultrasonic at-
tenuation of the calcaneum could be up to 50% larger
depending on the direction from which quantitative
ultrasound was measured. Cadaveric studies51 have
found different bone mineral densities between the
medial and lateral sides of the calcaneus using quanti-
tative ultrasound. These findings may be partially ex-
plained by the gait alterations seen in patients with
rheumatoid arthritis, where significant foot involve-
ment is reported to be an important cause of walking
difficulty.47, 52 Joint range of motion and immobiliza-
tion due to either recurrent flares of the disease or
deformation of joints could lead to loss of mobility,
thus reducing the loading response required to main-
tain healthy bone. Bone trabeculae thin with age, and
bone that is no longer subjected to biomechanical
stress will undergo rapid resorption.53 The present
study investigated the correlation between two pe-
ripheral scanning methods because it is possible that
axial skeletal sites are not the most relevant sites to
scan for osteoporosis in people with rheumatoid
arthritis given its pathogenesis.27
In terms of the methodologic quality of this study,
there are three areas worthy of discussion. Should
the study be repeated, the inclusion of an axial DEXA
measurement (eg, lumbar spine or hip) would be val-
uable. This may help determine the relative impor-
tance of issues such as the positioning of fixed trans-
ducers and the effect of calcaneal or ulnar deviation
on the results. This is important because DEXA meas-
ures in two dimensions,10 whereas quantitative ultra-
sound is thought to measure in three dimensions.41
The addition of a linear potentiometer to measure the
aperture between transducers would potentially allow
for bone width to be calculated, thus bringing a three-
dimensional element to bone density measurement.
The use of an instrument to measure function (eg,
the Health Assessment Questionnaire54 or the Foot
Function Index55) may have 1) provided information
as to the amount of weightbearing activity undertak-
en by the participant and, therefore, the risk of osteo-
porosis and 2) identified any participants currently
experiencing a flare of the disease because confined
areas of inflammation can induce localized osteope-
nia, thus influencing bone density measurements.29
Finally, the management of rheumatoid arthritis it-
self may also have a bearing on the results of this
study. In the contemporary management of rheuma-
toid arthritis, glucocorticosteroid medication may be
used to reduce disease activity in the short term, or in
lower doses to control mild disease. However, the
wide range of adverse effects (including osteoporo-
sis) and the introduction of newer disease-modifying
agents now make corticosteroids unsuitable for long-
term use.11, 56 The osteoporotic adverse effects of cor-
ticosteroids are most apparent in the regions of the
skeleton with high trabecular bone content.57 There-
fore, there could be a greater degree of bone loss in
the calcaneum (95% trabecular bone) compared with
the wrist, which contains 20% trabecular bone in the
radius. More precise information relating to the dose
and duration of glucocorticosteroid drugs might be
worthy of subgroup analysis. However, ascertaining
details from participants that were precise enough to
facilitate further analysis proved to be difficult.
Recommendations for the management of osteo-
porosis involve early diagnosis and appropriate treat-
ment.58 Identifying people who have osteoporosis be-
fore a fracture occurs and enabling targeted preventive
therapy remains a challenge, particularly in rheuma-
toid arthritis, where there is a need for a cost-effective
reproducible marker of osteoporotic progression.27Journal of the American Podiatric Medical Association • Vol 97 • No 2 • March/April 2007 113
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Conclusion
Although the CUBA scans in this study may not be
suitable for diagnosing osteoporosis, they may have a
role in identifying individuals with normal bone den-
sity. To improve the diagnostic potential of CUBA,
further work is recommended regarding calcaneal
and transducer positioning of CUBA units. In addi-
tion, consideration should be given to the possibility
of a wider role for quantitative ultrasound scanning
for normal bone density in people with rheumatoid
arthritis.
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